Biomedical subjects

Y Hatanaka

Publications and source records attributed to Y Hatanaka.

165 records · Page 10Linked to original sources

PubMedDate not supplied

Clinical effects of a polyethylene glycol grafted cellulose membrane on thrombogenicity and biocompatibility during hemodialysis.

The biocompatibility and thrombogenicity of polyethylene-glycol (PEG)-grafted cellulose hemodialysis (HD) membranes (PEGC) were investigated in cross-over HD of five HD patients with ordinary cellulose (OC). The PEGC significantly suppressed transient leukocyte and thrombocytopenia, and release of C3a, beta-thromboglobulin and platelet factor 4, in corresponding with the quantity of grafted PEG. HD with PEGC resulted in lower granulocyte elastase production, protein and blood cells adsorption on the membrane surface than those with OC. Minimum heparin in HD with PEGC was three times lower than that with OC, with the thrombin-antithrombin III complex elevation lower than that in HD with OC. The results indicate that the grafted PEG effectively suppresses blood and membrane interaction, thus improving biocompatibility and reducing thrombogenicity in clinical HD.

Biocompatible Materials↗

PubMedDate not supplied

External radiation therapy of prostatic carcinoma and its relationship to hormonal therapy.

From 1980 to 1990, a total of 54 patients with prostatic carcinoma were treated with external radiation therapy at the Kumamoto National Hospital. Ten patients were classified as Stage B, 22 as Stage C, and another 22 as Stage D according to the American Urological Association Clinical Staging System. The 5-year survival for all 54 patients was 30%. The 5-year disease-specific survival was 67% for Stage B, 47% for Stage C, and 26% for Stage D. The 5-year survival was 43% for patients in whom radiation therapy was initiated immediately after the first diagnosis or with less than one year of hormonal therapy, while it was 0% for patients in whom radiation therapy was initiated after more than one year of hormonal therapy (p = 0.01). The cause of intercurrent death was acute myocardial infarction in four patients and acute cardiac failure in one. Four of these patients received hormonal therapy for more than one year. The incidence of radiation-induced proctitis was not severe. This study suggests that long-term hormonal therapy prior to radiation therapy worsens the prognosis of patients with prostatic carcinoma.

Aged↗

PubMedDate not supplied

Transjugular intrahepatic portosystemic shunt: initial clinical experience and three-year follow-up.

To define the role of transjugular intrahepatic portosystemic shunt (TIPS), we prospectively studied 12 patients undergoing this procedure for variceal bleeding, refractory ascites, and hemorrhagic gastropathy due to portal hypertension. The TIPS creation was successful in 11 patients, and portal pressure immediately decreased an average of 8.3 cm H2O. Esophageal varices improved in six of seven patients, but gastric varices with spleno- or gastro-renal shunt did not change in three of four patients. A hemorrhage from portal hypertensive gastropathy was controlled immediately. Ascites improved in all six patients. Hepatic encephalopathy newly developed in four patients, but was controllable with medical treatment. During the follow-up period (mean, 25 months), shunt dysfunction was evident in eight of 10 patients. Stenosis and occlusion of the shunt were successfully treated by redilatation and/or placement of an additional stent. The cumulative survival rate was 73% at one year and 64% at two years. These results suggest that TIPS is a safe and effective treatment for uncontrollable complications due to portal hypertension, but is not effective for gastric varices with spleno- or gastro-renal shunt. Careful follow-up and shunt revision are necessary for the maintenance of shunt patency.

Adult↗